Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
By H. Hurwitz, L. Fehrenbacher, John Hainsworth, W. Heim, J. Berlin, E. Holmgren, J. Hambleton, W. Novotny, F. Kabbinavar. Journal of Clinical Oncology, 2005
708 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/8194d943e392450bac0c6788b76935e56ff0acad
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer (2015, positive): “(1) Patients appropriate for intensive therapy (a) When patient has become refractory or intolerant to the first-line regimen, including OX • FOLFIRI [61] +Bmab [80] • IRIS note 5 [81] • IRI [82] • FOLFIRI (or IRI) + Cmab/Pmab [82, 83] (b) When the patient has become refractory or intolerant to the ”
- Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. (2008, background): “Drugs that target VEGF and VEGFR-2 have made a major impact in cancer therapy.(1,2,4,17-20) Recently, E2100 demonstrated an improvement in RR and PFS with the addition of bevacizumab to paclitaxel in the first-line metastatic setting of breast cancer.”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (2011, neutral): “(2) FOLFIRI(6) [34, 35] ± bevacizumab [36, 37] (3) FOLFOX ± cetuximab/panitumumab [38, 39] (4) FOLFIRI ± cetuximab/panitumumab [40, 41] (5) 5-FU ? LV [42] ± bevacizumab [43, 44] or UFT ? LV [45] FOLFIRI bevacizumab* or CPT-11”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, neutral): “(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient ”